Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Daniel J, Freeman"'
Autor:
Yariv Mazor, Robert W. Wilkinson, Daniel J. Freeman, Ikbel Achour, William Dall'Acqua, Aleksandra D. Toloczko, Thomas V. Murray, Frances Neal, Gareth J. Browne, Godfrey J. Rainey, Michelle Morrow, Asis Palazon, Yanli Wu, James Dodgson, Michael G. Overstreet, Yaya Wang, Kathy Mulgrew, Stacy Kentner, Xiaofang Jin, Arthur Lewis, Kapil Vashisht, Shelby D. Gainer, Deepa S. Subramaniam, Ben Tran, Seock-Ah Im, Bo Wang, Sumati Hasani, Des C. Jones, James Hair, Anna Hansen, Lorraine Irving, Suzanne I. Sitnikova, Chunning Yang, Matthew J. Elder, Simon J. Dovedi
Supplementary Materials and Methods, and Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::238b4ab5c831dd6063dffdf564c8ad3c
https://doi.org/10.1158/2159-8290.22540037
https://doi.org/10.1158/2159-8290.22540037
Autor:
Yariv Mazor, Robert W. Wilkinson, Daniel J. Freeman, Ikbel Achour, William Dall'Acqua, Aleksandra D. Toloczko, Thomas V. Murray, Frances Neal, Gareth J. Browne, Godfrey J. Rainey, Michelle Morrow, Asis Palazon, Yanli Wu, James Dodgson, Michael G. Overstreet, Yaya Wang, Kathy Mulgrew, Stacy Kentner, Xiaofang Jin, Arthur Lewis, Kapil Vashisht, Shelby D. Gainer, Deepa S. Subramaniam, Ben Tran, Seock-Ah Im, Bo Wang, Sumati Hasani, Des C. Jones, James Hair, Anna Hansen, Lorraine Irving, Suzanne I. Sitnikova, Chunning Yang, Matthew J. Elder, Simon J. Dovedi
The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition but is commensurate with significant immune-related adverse events suboptimally limiting the doses of anti-CTLA4 mAb that can be used. MEDI5752 is a monovalent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ca7eaed273b219faf1bb63ec9cf8694
https://doi.org/10.1158/2159-8290.c.6549263
https://doi.org/10.1158/2159-8290.c.6549263
Autor:
Jeanne Mendell, Daniel J. Freeman, Wenqin Feng, Thore Hettmann, Matthias Schneider, Sabine Blum, Jens Ruhe, Johannes Bange, Kenji Nakamaru, Shuquan Chen, Zenta Tsuchihashi, Joachim von Pawel, Catherine Copigneaux, Robert A. Beckman
Publikováno v:
EBioMedicine, Vol 2, Iss 3, Pp 264-271 (2015)
Background: During early clinical development, prospective identification of a predictive biomarker and validation of an assay method may not always be feasible. Dichotomizing a continuous biomarker measure to classify responders also leads to challe
Externí odkaz:
https://doaj.org/article/7234004e5d4f47c7ab14202b186df656
Autor:
Bo Wang, Frances Neal, Arthur Lewis, Kapil Vashisht, Deepa S. Subramaniam, Des C. Jones, Sumati Hasani, Daniel J. Freeman, Chunning Yang, Lorraine Irving, Michael G. Overstreet, Gareth J. Browne, Suzanne I. Sitnikova, James Hair, Robert W. Wilkinson, Yaya Wang, Ben Tran, Ikbel Achour, James Dodgson, Shelby D. Gainer, Xiaofang Jin, Seock-Ah Im, William F Dall'Acqua, Yariv Mazor, Godfrey Rainey, Asis Palazon, Anna Hansen, Yanli Wu, Matthew J. Elder, Stacy Kentner, Aleksandra D. Toloczko, Michelle Morrow, Murray Thomas Vincent, Simon J. Dovedi, Kathy Mulgrew
Publikováno v:
Cancer Discovery. 11:1100-1117
The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition but is commensurate with significant immune-related adverse events suboptimally limiting the doses of anti-CTLA4 mAb that can be used. MEDI5752 is a monovalent
Autor:
Michael J. Boedigheimer, Daniel J. Freeman, Panteha Kiaei, Michael A. Damore, Robert Radinsky
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 15, Iss 2, Pp 125-132 (2013)
Background Epidermal growth factor receptor (EGFR)-targeted agents have demonstrated clinical benefit in patients with cancer. Identifying tissue-of-origin-independent predictive biomarkers is important to optimally treat patients. We sought to ident
Externí odkaz:
https://doaj.org/article/a3e3b8b14754452280b834422ca755f5
Autor:
Simon J, Dovedi, Matthew J, Elder, Chunning, Yang, Suzanne I, Sitnikova, Lorraine, Irving, Anna, Hansen, James, Hair, Des C, Jones, Sumati, Hasani, Bo, Wang, Seock-Ah, Im, Ben, Tran, Deepa S, Subramaniam, Shelby D, Gainer, Kapil, Vashisht, Arthur, Lewis, Xiaofang, Jin, Stacy, Kentner, Kathy, Mulgrew, Yaya, Wang, Michael G, Overstreet, James, Dodgson, Yanli, Wu, Asis, Palazon, Michelle, Morrow, Godfrey J, Rainey, Gareth J, Browne, Frances, Neal, Thomas V, Murray, Aleksandra D, Toloczko, William, Dall'Acqua, Ikbel, Achour, Daniel J, Freeman, Robert W, Wilkinson, Yariv, Mazor
Publikováno v:
Cancer discovery. 11(5)
The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition but is commensurate with significant immune-related adverse events suboptimally limiting the doses of anti-CTLA4 mAb that can be used. MEDI5752 is a monovalent
Publikováno v:
Nature reviews. Drug discovery. 18(9)
In the wake of the success of modern immunotherapy, oncolytic viruses (OVs) are currently seen as a potential therapeutic option for patients with cancer who do not respond or fail to achieve durable responses following treatment with immune checkpoi
Autor:
Kenji Nakamaru, Daniel J. Freeman, Catherine Copigneaux, Jens Ruhe, Johannes Bange, Thore Hettmann, Jeanne Mendell, Joachim von Pawel, Sabine Blum, Matthias Schneider, Zenta Tsuchihashi, Robert A. Beckman, Wenqin Feng, Shuquan Chen
Publikováno v:
EBioMedicine, Vol 2, Iss 3, Pp 264-271 (2015)
EBioMedicine
EBioMedicine
Background During early clinical development, prospective identification of a predictive biomarker and validation of an assay method may not always be feasible. Dichotomizing a continuous biomarker measure to classify responders also leads to challen
Autor:
Yunxin Bo, Tisha San Miguel, Nobuko Nishimura, Jian Jiang, Douglas A. Whittington, Paul E. Hughes, Sean Caenepeel, Mark H. Norman, John D. McCarter, Erin L. Mullady, Daniel J. Freeman, Kevin Yang, Ryan Wurz, Longbin Liu, Raju Subramanian, Kristin L. Andrews, Ling Wang, Liping H. Pettus, Nancy Zhang
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 22:5714-5720
Phosphoinositide 3-kinase (PI3K) is an important target in oncology due to the deregulation of the PI3K/Akt signaling pathway in a wide variety of tumors. A series of 4-amino-6-methyl-1,3,5-triazine sulfonamides were synthesized and evaluated as inhi
Autor:
Bradley J. Herberich, Tian Wu, Paul E. Hughes, Claire L. M. Jackson, Nobuko Nishimura, Nancy Zhang, Ryan Wurz, Douglas A. Whittington, Shon Booker, Sean Caenepeel, Tisha San Miguel, Jian Jiang, Anthony B. Reed, Adrian L. Smith, Seifu Tadesse, Brian A. Lanman, Andrew Tasker, Erin L. Mullady, John D. McCarter, Fang-Tsao Hong, Liping H. Pettus, Divesh Aidasani, Victor J. Cee, Ling Wang, Bin Wu, Mark H. Norman, Daniel J. Freeman, Kevin Yang, Longbin Liu, Leeanne Zalameda, Yunxin Y. Bo, Xiaochun Zhu, Kristin L. Andrews, Markian Stec, Nuria A. Tamayo, Raju Subramanian, Noel D'angelo
Publikováno v:
Journal of Medicinal Chemistry. 55:7796-7816
The phosphoinositide 3-kinase family catalyzes the phosphorylation of phosphatidylinositol-4,5-diphosphate to phosphatidylinositol-3,4,5-triphosphate, a secondary messenger which plays a critical role in important cellular functions such as metabolis